-
Mashup Score: 0FDA Expands Enhertu Indication to HER2-Positive Solid Tumors - 17 day(s) ago
The agent had already been approved for several cancer types.
Source: www.mdedge.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Black patients had more than two times the risk of dying from their cancer and they are underrepresented in clinical trials.
Source: www.mdedge.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Plant-Based Diet a Boon for Men With Prostate Cancer - 2 month(s) ago
A diet of fresh vegetables and fruit with few animal-based products is linked to reduced risk for recurrent prostate cancer, says study.
Source: www.mdedge.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Living in a Food Swamp Tied to High Breast Cancer Mortality - 4 month(s) ago
New research shows higher postmenopausal breast cancer mortality in communities with easier access to unhealthy fast food.
Source: www.mdedge.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Key clinical point: In women with locally advanced breast cancer (LABC) who received ne
Source: www.mdedge.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy - 6 month(s) ago
This review summarizes prior data regarding adjuvant and neo-adjuvant chemotherapy in non-small cell lung cancer and elaborates on results from the newer trials
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut - 6 month(s) ago
Key Points. Time-limited triple therapy leads to high rates of undetectable minimal residual disease and sustained remissions in high-risk CLL.Adverse events oc
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0How I treat non-transfusion-dependent β-thalassemia - 6 month(s) ago
Saliba and colleagues use 4 illustrative cases to delineate diagnosis and treatment of non-transfusion-dependent β-thalassemia. The authors discuss their approa
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0SABR could defer systemic therapy in oligoprogressive breast cancer - 7 month(s) ago
“We found surprisingly that SABR delayed a change in therapy by 10 months, which is great for patients.”
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0What is the future for multicancer early-detection tests? - 7 month(s) ago
Liquid biopsies based on genomic biomarkers could make MCED a reality, especially for cancers for which there is no standard screening process.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
#FDA Expands #Enhertu Indication to #HER2-Positive Solid Tumors 👉https://t.co/kFt7Q2y0JQ